Extracorporeal photopheresis induces NETosis in neutrophils derived from patients with chronic graft-vs-host disease.
extracorporeal photopheresis (ECP)
graft vs host disease (GVHD)
neutrophil extracellular traps (NETs)
Journal
Journal of clinical apheresis
ISSN: 1098-1101
Titre abrégé: J Clin Apher
Pays: United States
ID NLM: 8216305
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
revised:
25
05
2023
received:
15
11
2022
accepted:
26
06
2023
pubmed:
13
7
2023
medline:
13
7
2023
entrez:
13
7
2023
Statut:
ppublish
Résumé
Extracorporeal photopheresis (ECP) is considered an effective treatment for patients with chronic graft vs host disease (cGVHD) and demonstrates efficacy in ameliorating GVHD. The mechanism by which ECP acts against cGVHD is not fully understood. Preliminary observations have hinted at the potential involvement of neutrophil extracellular traps (NETs) formation in the pathogenesis of cGVHD. We aimed to assess the influence of ECP on the formation of NETs in patients with cGVHD as a potential mechanism in this setting. Patients treated with ECP for cGVHD at the Rabin Medical Center were included in this study. Blood samples were obtained at three different time points: before starting an ECP cycle, at the end of the first day of treatment, and 24 h following the initiation of the ECP treatment cycle. Neutrophils were harvested from all blood samples. NET formation was assessed by measurement of NET-bound specific neutrophil elastase activity and by immunofluorescence staining. Six patients (two females and four males) with cGVHD were included in the study. We observed a significant increase in NET formation among all six patients following ECP. Net-bound specific neutrophil elastase activity was elevated from a median value of 2.23 mU/mL (interquartile range [IQR] 2.06-2.47 mU/mL) at baseline to a median value of 13.06 mU/mL (IQR 10.27-15.97 mU/mL) immediately after the treatment and to a peak median value of 14.73 mU/mL (IQR 9.6-22.38 mU/mL) 24 h following the initiation of the ECP cycle. A qualitative assessment of NET formation using immunofluorescence staining has demonstrated markedly increased expression of citrullinated histone H3, a marker of NET formation, following ECP treatment. Our preliminary data indicate that ECP induces NET formation among patients with cGVHD. The contribution of increased NET formation to the therapeutic effect of cGVHD should be further investigated.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
615-621Informations de copyright
© 2023 The Authors. Journal of Clinical Apheresis published by Wiley Periodicals LLC.
Références
Flowers MED, Martin PJ. How we treat chronic graft-versus-host disease. Blood. 2015;125(4):606-615.
Miklos D, Cutler CS, Arora M, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130(21):2243-2250.
Zeiser R, von Bubnoff N, Butler J, et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020;382(19):1800-1810.
Zhang H, Chen R, Cheng J, Jin N, Chen B. Systematic review and meta-analysis of prospective studies for ECP treatment in patients with steroid-refractory acute GVHD. Patient Prefer Adherence. 2015;9:105-111.
Das-Gupta E, Greinix H, Jacobs R, et al. Extracorporeal photopheresis as second-line treatment for acute graft-versus-host disease: impact on six-month freedom from treatment failure. Haematologica. 2014;99(11):1746-1752.
Greinix HT, van Besien K, Elmaagacli AH, et al. Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis-results of a crossover randomized study. Biol Blood Marrow Transplant. 2011;17(12):1775-1782. doi:10.1016/j.bbmt.2011.05.004
Greinix HT, Socié G, Bacigalupo A, et al. Assessing the potential role of photopheresis in hematopoietic stem cell transplant. Bone Marrow Transplant. 2006;38(4):265-273.
Drexler B, Buser A, Infanti L, Stehle G, Halter J, Holbro A. Extracorporeal photopheresis in graft-versus-host disease. Transfus Med Hemother. 2020;47(3):214-225.
Jagasia M, Scheid C, Socié G, et al. Randomized controlled study of ECP with methoxsalen as first-line treatment of patients with moderate to severe cGVHD. Blood Adv. 2019;3(14):2218-2229.
Kansu E, Ward D, Sanchez AP, et al. Extracorporeal photopheresis for the treatment of chronic graft versus host disease. Hematology. 2022;27(1):785-794.
Niittyvuopio R, Juvonen E, Heiskanen J, et al. Extracorporeal photopheresis in the treatment of acute graft-versus-host disease: a single-center experience. Transfusion. 2018;58(8):1973-1979.
Greinix HT, Ayuk F, Zeiser R. Extracorporeal photopheresis in acute and chronic steroid-refractory graft-versus-host disease: an evolving treatment landscape. Leukemia. 2022;36(11):2558-2566.
Das-Gupta E, Dignan F, Shaw B, et al. Extracorporeal photopheresis for treatment of adults and children with acute GVHD: UK consensus statement and review of published literature. Bone Marrow Transplant. 2014;49(10):1251-1258.
Vieyra P, Wolf P. Extracorporeal Photopheresis: a case of immunotherapy ahead of its time. Transfus Med Hemother. 2020;47:226-235.
Cho A, Jantschitsch C, Knobler R. Extracorporeal photopheresis-an overview. Front Med. 2018;5:236.
Edelson R, Wu Y, Schneiderman J. American council on ECP (ACE): why now? J Clin Apher. 2018;33(4):464-468.
Piccirillo N, Putzulu R, Massini G, et al. Inline extracorporeal photopheresis: evaluation of cell collection efficiency. Transfusion. 2019;59(12):3714-3720.
Schwab L, Goroncy L, Palaniyandi S, et al. Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage. Nat Med. 2014;20(6):648-654.
Byun YS, Yoo YS, Kang MJ, et al. Marked infiltration of neutrophils at the upper palpebral conjunctiva in patients with chronic graft-versus-host disease. Ocul Surf. 2019;17(2):295-302. doi:10.1016/j.jtos.2018.12.007
Hülsdünker J, Ottmüller KJ, Neeff HP, et al. Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset. Blood. 2018;131:1858-1869.
Martin PJ. Pathogenic neutrophils in acute GVHD. Blood. 2018;131(16):1774-1775.
Franklin C, Cesko E, Hillen U, Schilling B, Brandau S. Modulation and apoptosis of neutrophil granulocytes by extracorporeal photopheresis in the treatment of chronic graft-versus-host disease. PloS One. 2015;10:e0134518.
Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004;303:1532-1535.
Barnado A, Crofford LJ, Oates JC. At the bedside: neutrophil extracellular traps (NETs) as targets for biomarkers and therapies in autoimmune diseases. J Leukoc Biol. 2016;99(2):265-278.
Martinod K, Wagner DD. Thrombosis: tangled up in NETs. Blood. 2014;123(18):2768-2776.
Gloude NJ, Khandelwal P, Luebbering N, et al. Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD. Blood. 2017;130(10):1259-1266.
An S, Raju I, Surenkhuu B, et al. Neutrophil extracellular traps (NETs) contribute to pathological changes of ocular graft-vs.-host disease (oGVHD) dry eye: implications for novel biomarkers and therapeutic strategies. Ocul Surf. 2019;17(3):589-614. doi:10.1016/j.jtos.2019.03.010
Knobler R, Berlin G, Calzavara-Pinton P, et al. Guidelines on the use of extracorporeal photopheresis. J Eur Acad Dermatol Venereol. 2014;28(suppl. 1):1-37.
Mallinckrodt. THERAKOS® CELLEX® Photopheresis System Operator's Manual 1470493_Rev06_EN-US. 2019.
Lahoz-Beneytez J, Elemans M, Zhang Y, et al. Human neutrophil kinetics: modeling of stable isotope labeling data supports short blood neutrophil half-lives. Blood. 2016;127(26):3431-3438.
Kasarskis EJ, Berryman S, Vanderleest JG, Schneider AR, McClain CJ. Nutritional status of patients with amyotrophic lateral sclerosis: relation to the proximity of death. Am J Clin Nutr. 1996;63(1):130-137.
Wolach O, Sellar RS, Martinod K, et al. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med. 2018;10(436):eaan8292.
Neubert E, Bach KM, Busse J, et al. Blue and long-wave ultraviolet light induce in vitro neutrophil extracellular trap (NET) formation. Front Immunol. 2019;10:2428.
Zawrotniak M, Bartnicka D, Rapala-Kozik M. UVA and UVB radiation induce the formation of neutrophil extracellular traps by human polymorphonuclear cells. J Photochem Photobiol B. 2019;196:111511.
Teijeira Á, Garasa S, Gato M, et al. CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity. Immunity. 2020;52(5):856-871.e8.
Jiang H, Fu D, Bidgoli A, Paczesny S. T cell subsets in graft versus host disease and graft versus tumor. Front Immunol. 2021;12:761448.
Beres AJ, Haribhai D, Chadwick AC, Gonyo PJ, Williams CB, Drobyski WR. CD8+ Foxp3+ regulatory T cells are induced during graft-versus-host disease and mitigate disease severity. J Immunol. 2012;189(1):464-474.
Sawamukai N, Satake A, Schmidt AM, et al. Cell-autonomous role of TGFβ and IL-2 receptors in CD4+ and CD8+ inducible regulatory T-cell generation during GVHD. Blood. 2012;119(23):5575-5583.
Dekker L, Sanders E, Lindemans CA, de Koning C, Nierkens S. Naive T cells in graft versus host disease and graft versus leukemia: innocent or guilty? Front Immunol. 2022;13:893545.
Salomon BL, Sudres M, Cohen JL. Regulatory T cells in graft-versus-host disease. Springer Semin Immunopathol. 2006;28(1):25-29.
Belizaire R, Kim HT, Poryanda SJ, et al. Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease. Blood Adv. 2019;3(7):969-979.